We still like JNJ despite lawsuit risk

Article Excerpt

Medical products giant Johnson & Johnson recently spun off its consumer products business as a separate firm called Kenvue. The company first sold shares in Kenvue to the public in May 2023 at $22.00 a share. Johnson & Johnson later let its own shareholders exchange their shares for Kenvue shares at a 7% discount. It still holds 9.5% of Kenvue. Since the IPO, Johnson & Johnson shares are down 6%. That’s partly due to concerns over lawsuits claiming its talc baby powder causes ovarian cancer. The company is moving to settle those suits, which should cut its risk. As for Kenvue, its down 9%. That’s partly due to a class action lawsuit alleging its Tylenol pain reliever may contribute to autism in children. We still like its long-term outlook, but prefer the former parent for your new buying. JOHNSON & JOHNSON $153 is your #1 Spinoff Buy for 2023. The company (New York symbol JNJ; Manufacturing sector; Shares outstanding: 2.4 billion; Market cap: $367.2 billion; Dividend…